Apogee Therapeutics (APGE) to Release Quarterly Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is projected to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:00 PM ET.

Apogee Therapeutics Trading Down 0.8%

Shares of NASDAQ APGE opened at $68.39 on Monday. Apogee Therapeutics has a one year low of $26.20 and a one year high of $84.56. The business has a 50-day moving average price of $73.68 and a two-hundred day moving average price of $58.60. The firm has a market capitalization of $4.67 billion, a PE ratio of -15.61 and a beta of 1.42.

Wall Street Analysts Forecast Growth

APGE has been the topic of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $95.00 price objective on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Stephens initiated coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 16th. They set an “overweight” rating and a $95.00 target price for the company. Stifel Nicolaus set a $133.00 price target on shares of Apogee Therapeutics in a report on Tuesday, January 6th. UBS Group upgraded Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Finally, BTIG Research set a $137.00 price objective on Apogee Therapeutics in a research report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.58.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the completion of the sale, the director owned 298,647 shares in the company, valued at approximately $22,786,766.10. This represents a 85.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $75.01, for a total value of $3,000,400.00. Following the completion of the transaction, the chief executive officer directly owned 1,232,987 shares in the company, valued at $92,486,354.87. The trade was a 3.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,885,100 shares of company stock valued at $143,557,153 over the last three months. 42.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors have recently modified their holdings of APGE. T. Rowe Price Investment Management Inc. lifted its stake in shares of Apogee Therapeutics by 189,522.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock worth $206,246,000 after buying an additional 2,731,015 shares during the last quarter. Invesco Ltd. raised its holdings in Apogee Therapeutics by 142.6% in the 4th quarter. Invesco Ltd. now owns 70,687 shares of the company’s stock worth $5,335,000 after acquiring an additional 41,549 shares during the period. Vident Advisory LLC bought a new position in Apogee Therapeutics in the 4th quarter worth $218,000. XTX Topco Ltd lifted its position in Apogee Therapeutics by 225.1% during the 4th quarter. XTX Topco Ltd now owns 19,026 shares of the company’s stock worth $1,436,000 after acquiring an additional 13,174 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in Apogee Therapeutics by 29.4% during the fourth quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock valued at $41,514,000 after acquiring an additional 125,000 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.